Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

The RBA’s proposed surcharge ban and fee caps may reshape payments, but Visa and Mastercard are already positioned for the ...

Explore U.S. economic trends: growth uncertainty and rising inflation risks.

Australian bonds experienced a resurgence, posting their best financial year since 2018/19. Some managers returned close to ...

In a market full of flashy tech and speculative growth stories, here's a refreshingly grounded stock to watch.

Over the last 12 months to 30 June 2025, Bloomberg data revealed that CBA alone accounted for 33% of the S&P/ASX 200’s total ...

Rational investors have abandoned CBA, resulting in a share price that gets 'pushed around' by passive and momentum flows.

ARK strives to invest at the pace of innovation. The ARK Global Disruptive Innovation Fund aims to achieve a target average ...

By learning to avoid mistakes you can improve your returns as much by learning what qualities to look for in a business.

While markets chase the AI hype, medtech quietly trades at decade-lows. Here’s why that’s an opportunity for long-term ...

In this wire, we crunch the data on the country's top-performing Aussie equities funds for FY25 and examine their positioning ...

These days, it’s widely recognised that nuclear power will be a critical component of the global transition to clean energy.